• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对 Spike N 端结构域 N1/N2 环的奥密克戎特异性超强 SARS-CoV-2 中和抗体。

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.

机构信息

Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.

Changping Laboratory, Beijing, People's Republic of China.

出版信息

Emerg Microbes Infect. 2024 Dec;13(1):2412990. doi: 10.1080/22221751.2024.2412990. Epub 2024 Oct 28.

DOI:10.1080/22221751.2024.2412990
PMID:39361729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11520098/
Abstract

A multitude of functional mutations continue to emerge on the N-terminal domain (NTD) of the spike protein in SARS-CoV-2 Omicron subvariants. Understanding the immunogenicity of Omicron NTD and the properties of antibodies elicited by it is crucial for comprehending the impact of NTD mutations on viral fitness and guiding vaccine design. In this study, we find that most of NTD-targeting antibodies isolated from individuals with BA.5/BF.7 breakthrough infection (BTI) are ancestral (wild-type or WT)-reactive and non-neutralizing. Surprisingly, we identified five ultra-potent neutralizing antibodies (NAbs) that can only bind to Omicron but not WT NTD. Structural analysis revealed that they bind to a unique epitope on the N1/N2 loop of NTD and interact with the receptor-binding domain (RBD) via the light chain. These Omicron-specific NAbs achieve neutralization through ACE2 competition and blockage of ACE2-mediated S1 shedding. However, BA.2.86 and BA.2.87.1, which carry insertions or deletions on the N1/N2 loop, can evade these antibodies. Together, we provided a detailed map of the NTD-targeting antibody repertoire in the post-Omicron era, demonstrating their vulnerability to NTD mutations enabled by its evolutionary flexibility, despite their potent neutralization. These results revealed the function of the indels in the NTD of BA.2.86/JN.1 sublineage in evading neutralizing antibodies and highlighted the importance of considering the immunogenicity of NTD in vaccine design.

摘要

大量的功能突变继续出现在 SARS-CoV-2 奥密克戎亚变种的刺突蛋白的 N 端结构域(NTD)上。了解奥密克戎 NTD 的免疫原性以及由其引发的抗体特性,对于理解 NTD 突变对病毒适应性的影响以及指导疫苗设计至关重要。在这项研究中,我们发现,从 BA.5/BF.7 突破感染(BTI)个体中分离出的大多数 NTD 靶向抗体都是祖先(野生型或 WT)反应性和非中和性的。令人惊讶的是,我们鉴定了五个超强中和抗体(NAb),它们只能结合奥密克戎,而不能结合 WT NTD。结构分析表明,它们结合 NTD 的 N1/N2 环上的一个独特表位,并通过轻链与受体结合域(RBD)相互作用。这些奥密克戎特异性 NAb 通过 ACE2 竞争和阻断 ACE2 介导的 S1 脱落来实现中和。然而,在 N1/N2 环上带有插入或缺失的 BA.2.86 和 BA.2.87.1,可以逃避这些抗体。总之,我们提供了奥密克戎后时代 NTD 靶向抗体库的详细图谱,表明尽管它们具有强大的中和作用,但 NTD 突变使其具有进化灵活性,使这些抗体容易受到影响。这些结果揭示了 NTD 中的插入或缺失在 BA.2.86/JN.1 亚谱系逃避中和抗体中的作用,并强调了在疫苗设计中考虑 NTD 免疫原性的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/c671cf7db030/TEMI_A_2412990_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/bd653afdcd4e/TEMI_A_2412990_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/ce770aba45f3/TEMI_A_2412990_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/8fa10e24b46a/TEMI_A_2412990_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/c671cf7db030/TEMI_A_2412990_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/bd653afdcd4e/TEMI_A_2412990_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/ce770aba45f3/TEMI_A_2412990_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/8fa10e24b46a/TEMI_A_2412990_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd0f/11520098/c671cf7db030/TEMI_A_2412990_F0004_OC.jpg

相似文献

1
Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.针对 Spike N 端结构域 N1/N2 环的奥密克戎特异性超强 SARS-CoV-2 中和抗体。
Emerg Microbes Infect. 2024 Dec;13(1):2412990. doi: 10.1080/22221751.2024.2412990. Epub 2024 Oct 28.
2
AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.AlphaFold2 对 SARS-CoV-2 刺突奥密克戎 JN.1、KP.2 和 KP.3 变体构象集合的建模和分子动力学模拟:结合能突变分析揭示 ACE2 亲和力的上位驱动因素和抗体耐药性逃逸热点。
Viruses. 2024 Sep 13;16(9):1458. doi: 10.3390/v16091458.
3
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.识别 SARS-CoV-2 刺突蛋白主要和次要表位的单克隆抗体的中和效力受 B.1.1.7 变异株的影响。
Immunity. 2021 Jun 8;54(6):1276-1289.e6. doi: 10.1016/j.immuni.2021.03.023. Epub 2021 Apr 1.
4
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
5
Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.SARS-CoV-2 BA.2.86 和 JN.1 亚变种的进化和抗体逃逸的结构基础。
Nat Commun. 2024 Sep 4;15(1):7715. doi: 10.1038/s41467-024-51973-8.
6
Glycan masking of NTD loops with a chimeric RBD of the spike protein as a vaccine design strategy against emerging SARS-CoV-2 Omicron variants.用 Spike 蛋白嵌合 RBD 对 NTD 环进行聚糖掩蔽作为针对新型 SARS-CoV-2 奥密克戎变异株的疫苗设计策略。
J Med Virol. 2024 Sep;96(9):e29893. doi: 10.1002/jmv.29893.
7
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.刺突蛋白结构特征、决定病毒进入宿主细胞的物种特异性血管紧张素转换酶 2 残基,以及奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 变异株的抗体中和逃逸。
J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24.
8
A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.受体结合域和 N 端结构域中和抗体的联合应用限制了 SARS-CoV-2 刺突蛋白中和逃逸突变体的产生。
mBio. 2021 Oct 26;12(5):e0247321. doi: 10.1128/mBio.02473-21. Epub 2021 Oct 5.
9
SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1.奥密克戎 BA.2.87.1 对血清中和的敏感性高于 EG.5.1 和 JN.1。
Emerg Microbes Infect. 2024 Dec;13(1):2359004. doi: 10.1080/22221751.2024.2359004. Epub 2024 May 31.
10
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.针对刺突蛋白受体结合域的强效病毒中和纳米抗体的新型 SARS-CoV-2 变体逃避的结构基础。
Biochemistry (Mosc). 2024 Jul;89(7):1260-1272. doi: 10.1134/S0006297924070083.

引用本文的文献

1
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection.不断演变的新冠病毒疫苗:从当前解决方案到广谱保护
Vaccines (Basel). 2025 Jun 12;13(6):635. doi: 10.3390/vaccines13060635.
2
SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)中和抗体的特异性在近期感染的婴儿和免疫印记个体之间存在显著差异。
J Virol. 2025 Apr 15;99(4):e0010925. doi: 10.1128/jvi.00109-25. Epub 2025 Mar 25.
3
SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.

本文引用的文献

1
Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant.奥密克戎变异株 EG.5.1 病毒学特征。
Microbiol Immunol. 2024 Sep;68(9):305-330. doi: 10.1111/1348-0421.13165. Epub 2024 Jul 4.
2
Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)KP.3、LB.1和KP.2.3变体的病毒学特征
Lancet Infect Dis. 2024 Aug;24(8):e482-e483. doi: 10.1016/S1473-3099(24)00415-8. Epub 2024 Jun 27.
3
Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.新型冠状病毒跳跃变异株BA.2.87.1的抗原性评估
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)中和抗体的特异性在近期感染的婴儿和免疫印记个体之间存在显著差异。
bioRxiv. 2025 Jan 20:2025.01.17.633612. doi: 10.1101/2025.01.17.633612.
4
Structural Immunology of SARS-CoV-2.新型冠状病毒的结构免疫学
Immunol Rev. 2025 Jan;329(1):e13431. doi: 10.1111/imr.13431. Epub 2024 Dec 27.
Emerg Microbes Infect. 2024 Dec;13(1):2343909. doi: 10.1080/22221751.2024.2343909. Epub 2024 May 2.
4
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.XBB.1.5 单价 mRNA 疫苗加强针可诱导针对 XBB 亚谱系和 JN.1 的强大中和抗体。
Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. doi: 10.1016/j.chom.2024.01.014. Epub 2024 Feb 19.
5
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.新型冠状病毒SARS-CoV-2 BA.2.86和FLip变体的免疫逃逸、传染性和融合性
Cell. 2024 Feb 1;187(3):585-595.e6. doi: 10.1016/j.cell.2023.12.026. Epub 2024 Jan 8.
6
Evolutionary deletions within the SARS-CoV-2 genome as signature trends for virus fitness and adaptation.SARS-CoV-2 基因组内的进化缺失是病毒适应和适应能力的特征趋势。
J Virol. 2024 Jan 23;98(1):e0140423. doi: 10.1128/jvi.01404-23. Epub 2023 Dec 13.
7
A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.一种广泛反应性的针对 SARS-CoV-2 刺突蛋白 N 端结构域的抗体可赋予 Fc 介导的保护作用。
Cell Rep Med. 2023 Dec 19;4(12):101305. doi: 10.1016/j.xcrm.2023.101305. Epub 2023 Nov 30.
8
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.多次感染奥密克戎会颠覆原始 SARS-CoV-2 免疫印记。
Nature. 2024 Jan;625(7993):148-156. doi: 10.1038/s41586-023-06753-7. Epub 2023 Nov 22.
9
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.SARS-CoV-2 BA.2.86 刺突蛋白的抗原性和受体亲和力。
Nature. 2023 Dec;624(7992):639-644. doi: 10.1038/s41586-023-06750-w. Epub 2023 Oct 23.
10
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking.靶向 SARS-CoV-2 刺突糖蛋白四元结构域的抗体通过构象锁定防止病毒受体结合。
Immunity. 2023 Oct 10;56(10):2442-2455.e8. doi: 10.1016/j.immuni.2023.09.003. Epub 2023 Sep 29.